Obesity - Pipeline Insight, 2021
This report can be delivered to the clients within 72 Hours
DelveInsight’s, “Obesity - Pipeline Insight, 2021,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Obesity pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Obesity: Overview
A person whose weight is higher than what is considered as a normal weight adjusted for height is described as being overweight or having obesity. Factors that may contribute to weight gain among adults and youth include genes, eating habits, physical inactivity, TV, computer, phone, and other screen time, sleep habits, medical conditions or medications, and where and how people live, including their access to healthy foods and safe places to be active. Overweight and obesity are risk factors for many health problems such as type 2 diabetes, high blood pressure, joint problems, and gallstones, among other conditions.
'Obesity - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Obesity pipeline landscape is provided which includes the disease overview and Obesity treatment guidelines. The assessment part of the report embraces, in depth Obesity commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Obesity collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Obesity report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Obesity Emerging Drugs
Further product details are provided in the report..
Obesity: Therapeutic Assessment
This segment of the report provides insights about the different Obesity drugs segregated based on following parameters that define the scope of the report, such as:
Obesity: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Obesity therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Obesity drugs.
Obesity Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Obesity - Pipeline Insight, 2021,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Obesity pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Obesity: Overview
A person whose weight is higher than what is considered as a normal weight adjusted for height is described as being overweight or having obesity. Factors that may contribute to weight gain among adults and youth include genes, eating habits, physical inactivity, TV, computer, phone, and other screen time, sleep habits, medical conditions or medications, and where and how people live, including their access to healthy foods and safe places to be active. Overweight and obesity are risk factors for many health problems such as type 2 diabetes, high blood pressure, joint problems, and gallstones, among other conditions.
'Obesity - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Obesity pipeline landscape is provided which includes the disease overview and Obesity treatment guidelines. The assessment part of the report embraces, in depth Obesity commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Obesity collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Obesity R&D. The therapies under development are focused on novel approaches to treat/improve Obesity.
This segment of the Obesity report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Obesity Emerging Drugs
- Tirzepatide: Eli Lilly and Company
- Danuglipron: Pfizer
- Noiiglutide: Jiangsu Hansoh Pharmaceutical
- MEDI 0382: MedImmune
Further product details are provided in the report..
Obesity: Therapeutic Assessment
This segment of the report provides insights about the different Obesity drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Obesity
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Obesity: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Obesity therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Obesity drugs.
Obesity Report Insights
- Obesity Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Obesity drugs?
- How many Obesity drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Obesity?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Obesity therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Obesity and their status?
- What are the key designations that have been granted to the emerging drugs?
- Eli Lilly and Company
- Pfizer
- Jiangsu Hansoh Pharmaceutical
- MedImmune
- Can-Fite Biopharma
- Novo Nordisk
- 10xBio
- Biolingus
- Shionogi
- Boehringer Ingelheim
- Saniona
- Diasome Pharmaceuticals
- Empros Pharma
- Amgen
- ERX Pharmaceuticals
- Innovent Biologics
- Otsuka Pharmaceutical
- Kyowa Kirin Co., Ltd.
- Raziel Therapeutics
- Hanmi Pharmaceutical
- YSOPIA Biosciences
- Allysta Pharmaceutical
- pH Pharma
- Gannex Pharma
- Neuraly, Inc.
- NGM Biopharmaceuticals, Inc
- Glaceum
- Carmot Therapeutics
- LG Chem. Life sciences
- CohBar
- Scohia Pharma
- Click Therapeutics
- YUHAN
- UGISense AG
- Kanion Huawe Pharmaceutical
- OPKO Health
- EraCal Therapeutics
- Kintai Therapeutics
- NovmetaPharma
- Tirzepatide
- Danuglipron
- Noiiglutide
- MEDI 0382
- Namodenoson
- NN 9838
- Polidocanol
- BL OPUS I
- Semaglutide subcutaneous
- S 237648
- NNC 01651875
- Peptide YY
- BI 456906
- LY 3305677
- Tesofensine
- HDV Biotin
- BI 1356225
- EMP16-02
- AMG 171
- ERX1000
- IBI362
- AMG 133
- BI 456906
- NO-13065
- Bardoxolone methyl
- RZL-012
- Efinopegdutide
- Xla1
- ALY688-SR
- PHP-303
- ASC 41
- DD01
- NGM395
- HSG4112
- CT-388
- LR19156
- LR19020
- CB4211
- SCO-272
- SCO-267
- SCO-094
- CT-181
- YH34160
- YHC2129
- YHC2134
- CT 868
- Metoprolol/tesofensine
- OPK-88003
- KTX-0200
- NovOB
Introduction
Executive Summary
Obesity: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Obesity – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Obesity companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Obesity Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Tirzepatide: Eli Lilly and Company
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
Danuglipron: Pfizer
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
Comparative Analysis
ERX1000: ERX Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Obesity Key Companies
Obesity Key Products
Obesity- Unmet Needs
Obesity- Market Drivers and Barriers
Obesity- Future Perspectives and Conclusion
Obesity Analyst Views
Obesity Key Companies
Appendix
Executive Summary
Obesity: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Obesity – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Obesity companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Obesity Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Tirzepatide: Eli Lilly and Company
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
Danuglipron: Pfizer
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
Comparative Analysis
ERX1000: ERX Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Obesity Key Companies
Obesity Key Products
Obesity- Unmet Needs
Obesity- Market Drivers and Barriers
Obesity- Future Perspectives and Conclusion
Obesity Analyst Views
Obesity Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Obesity
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Obesity
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Obesity
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Obesity
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
